Editorial: Epigenetic therapy against cancer: toward new molecular targets and technologies

Ângela Sousa; Christiane P Soares; Chung Man Chin; Daniela Trisciuoglio; Fatima Valdes-Mora

doi:10.3389/fcell.2023.1218986

Editorial: Epigenetic therapy against cancer: toward new molecular targets and technologies

Front Cell Dev Biol. 2023 May 24:11:1218986. doi: 10.3389/fcell.2023.1218986. eCollection 2023.

Authors

Ângela Sousa¹, Christiane P Soares², Chung Man Chin^{2

3}, Daniela Trisciuoglio⁴, Fatima Valdes-Mora^{5

6}

Affiliations

¹ CICS-UBI-Health Science Research Centre, University of Beira Interior, Covilhã, Portugal.
² School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil.
³ School of Medicine, UNION of the Colleges of the GREAT LAKES (UNILAGO), Sao José do Rio Preto, Brazil.
⁴ IBPM Institute of Molecular Biology and Pathology, CNR National Research Council, C/o Department of Biology and Biotechnology "Charles Darwin", Sapienza University of Rome, Rome, Italy.
⁵ Children's Cancer Institute Australia Randwick, Randwick, NSW, Australia.
⁶ Garvan Institute of Medical Research Darlinghurst, Darlinghurst, NSW, Australia.

No abstract available

Keywords: cancer therapy; epigenetics; histone deacetylases; inhibitors; prognostic biomarker; tumor microenvironment.

Publication types

Editorial

Grants and funding

ÂS was supported by CICS-UBI projects UIDB/00709/2020 and UIDP/00709/2020, financed by national funds through the Portuguese Foundation for Science and Technology/MCTES. CC is supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) PROC. 2019/10746-6 and National Council for Scientific and Technological Development (CNPq) for productivity fellowship level 2 (CNPq process 306009/2022-6). DT was supported by Banca d’Italia Contributo liberale 2021and AIRCprojects under IG 2020-ID 24942.